Antios Raises $96m To Advance HBV Drug With Pharmasset Pedigree
Antios thinks ATI-2173, which employs the Pharmasset liver-targeting chemistry used in HCV blockbuster Sovaldi, can help produce a functional cure in hepatitis B combination therapy.
Antios thinks ATI-2173, which employs the Pharmasset liver-targeting chemistry used in HCV blockbuster Sovaldi, can help produce a functional cure in hepatitis B combination therapy.